Magnetic nanoparticles for drug delivery

Arruebo, Manuel; Fernández-Pacheco, Rodrigo; Ibarra, M. R.; Santamarı́a, Jesús

doi:10.1016/s1748-0132(07)70084-1

Cited by 1,488 publications

(979 citation statements)

References 101 publications

Supporting

Mentioning

932

Contrasting

Unclassified

Order By: Relevance

“…[344] Moreover, MNPs coated with silica are negatively charged at blood pH which results in avoiding the aggregate formation in body fluids. [345] Also, the transparent matrix of silica allows the efficient passage of excitation and emission light for better imaging diagnosis. [346] Modification of magnetite nanoparticles was firstly performed by Philipse et al [347] through a sol-gel approach.…”

Section: Silicamentioning

confidence: 99%

“…[604] In this regard, nanotechnology and drug delivery have merged into so-called "magic bullets," proposed firstly by Paul Ehrlich, to eliminate these substantial shortcomings by overcoming biological barriers and selectively reaching the cancerous tissues for on-demand release of their cargos in the optimal dosage range. [345] These novel drug delivery platforms offer attractive features to significantly improve the pharmacokinetics of conventional drugs by: (1) protecting drugs against harsh environments to increase the half-life of drugs, (2) providing specific targeting to spare healthy cells, (3) capability to ferry multiple types of anticancer drugs as well as imaging modalities, (4) and offering precise control over the drug release thanks to stimuli-responsive coating and material designs. [605] In one special case, there has been an increasing interest in loading the therapeutics on MNPs for magnetic drug targeting (MDT) which provides external means of guiding drug particles within the body.…”

Section: Magnetic Drug Targetingmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

193

171

View full text Add to dashboard Cite

In order to translate nanotechnology into medical practice, magnetic nanoparticles (MNPs) have been presented as a class of non‐invasive nanomaterials for numerous biomedical applications. In particular, MNPs have opened a door for simultaneous diagnosis and brisk treatment of diseases in the form of theranostic agents. This review highlights the recent advances in preparation and utilization of MNPs from the synthesis and functionalization steps to the final design consideration in evading the body immune system for therapeutic and diagnostic applications with addressing the most recent examples of the literature in each section. This study provides a conceptual framework of a wide range of synthetic routes classified mainly as wet chemistry, state‐of‐the‐art microfluidic reactors, and biogenic routes, along with the most popular coating materials to stabilize resultant MNPs. Additionally, key aspects of prolonging the half‐life of MNPs via overcoming the sequential biological barriers are covered through unraveling the biophysical interactions at the bio–nano interface and giving a set of criteria to efficiently modulate MNPs' physicochemical properties. Furthermore, concepts of passive and active targeting for successful cell internalization, by respectively exploiting the unique properties of cancers and novel targeting ligands are described in detail. Finally, this study extensively covers the recent developments in magnetic drug targeting and hyperthermia as therapeutic applications of MNPs. In addition, multi‐modal imaging via fusion of magnetic resonance imaging, and also innovative magnetic particle imaging with other imaging techniques for early diagnosis of diseases are extensively provided.

show abstract

Section: Silicamentioning

confidence: 99%

Section: Magnetic Drug Targetingmentioning

confidence: 99%

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Mosayebi

Kiyasatfar

Laurent

2017

Adv Healthcare Materials

193

171

View full text Add to dashboard Cite

show abstract

“…Except for nanothermotherapy, another possible and most promising application of MNPs is in drug delivery as carriers for chemotherapeutic agents for sustained or controlled delivery for cancer treatment. Compared with the organic materials including polymeric nanoparticles, liposomes and micelles under investigation as drug delivery nanovectors, the main advantages of MNPs as drug carriers summarized by 386 Manuel Arruebo can be: (i) visualized ( SPIONs for MRI); (ii) guided by means of permanent magnetic field; and (iii) heated in a magnetic field to trigger drug release and/or combined with hyperthermia (Arruebo 2007). These advantages can help to yield an improved treatment efficacy and reduction of unwanted side effects.…”

Section: Introductionmentioning

confidence: 99%

Magnetic Nanocomposite Devices for Cancer Thermochemotherapy

Zhao¹,

Wang²,

Yang³

et al. 2011

Advances in Nanocomposites - Synthesis, Characterization and Industrial Applications

View full text Add to dashboard Cite

“…The use of magnetic fields in medicine is FDA-approved, and its most common application is in diagnostics like MRI [12,13]. Recently, more interest has been placed on the possibility of magnetic drug targeting [12,14]. Co-encapsulation of nano-magnetites with insulin in liposomes or with microparticles for oral delivery has been shown to increase drug retention and absorption [10,11].…”

Section: Introductionmentioning

confidence: 99%

The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules

et al. 2008

View full text Add to dashboard Cite

Protein drugs have low bioavailability after oral administration, which is due in part to fast transit of the drugs or drug delivery vehicles through the gastrointestinal tract. Increasing the time that the drugs spend in the intestine after dosing would allow for greater absorption and increased bioavailability. We developed a formulation strategy that can be used to prolong intestinal retention of drug delivery vehicles without substantial alterations to current polymeric encapsulation strategies. A model drug, insulin, was encapsulated in negatively-charged poly(lactic-co-glycolic acid) (PLGA) microparticles, and the microparticles were subsequently mixed with positively-charged micromagnets, whose size will prevent them from being absorbed. Stable complexes formed through electrostatic interaction. The complexes were effectively immobilized in vitro in a model of the mouse small intestine by application of an external magnetic field. Mice that were gavaged with radio-labeled complexes and fitted with a magnetic belt retained 32.5% of the 125 I-insulin in the small intestine compared with 5.4% for the control group 6 hours after administration (p=0.005). Furthermore, mice similarly gavaged with complexes encapsulating insulin (120 Units/kg) exhibited long-term glucose reduction in the groups with magnetic belts. The corresponding bioavailability of insulin was 5.11% compared with 0.87% for the control group (p=0.007).• Correspondence to Robert Langer (Office

show abstract

Magnetic nanoparticles for drug delivery

Cited by 1,488 publications

References 101 publications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Synthesis, Functionalization, and Design of Magnetic Nanoparticles for Theranostic Applications

Magnetic Nanocomposite Devices for Cancer Thermochemotherapy

The use of charge-coupled polymeric microparticles and micromagnets for modulating the bioavailability of orally delivered macromolecules

Contact Info

Product

Resources

About